Morningstar

Boston Scientific Corp BSX

Morningstar Rating
Unlock
Stock XNYS Rating as of
$84.49 +0.35 (0.42%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Boston Scientific Sees Farapulse Gain Strength in Its Early Days

Debbie S. Wang

Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a prolonged period of operational and management upheaval from 2006 to 2014 wasn't enough to permanently impair Boston's underlying business or the organization's ability to develop and commercialize new technology platforms. Under CEO Michael Mahoney, the firm has focused on introducing novel technology and leveraging its historically formidable sales and marketing resources.

Read Full Report

Price vs Fair Value

View History
BSX is trading at a 76% premium.
Price
$84.49
Fair Value
$71.00
Uncertainty
Medium
1-Star Price
$988.10
5-Star Price
$91.20
Economic Moat
Njwfg
Capital Allocation
Grynfhkt

Bulls Say, Bears Say

Bulls

Boston remains one of the top players when it comes to intellectual property in the medical technology arena, which bodes well for its ability to innovate enough to keep up with rivals.

Bears

Boston's coronary stent business is less moaty than its cardiac rhythm management segment.

Show More

News

View All

Trading Information

Previous Close Price
$84.14
Day Range
$83.16–84.58
52-Week Range
$48.35–84.89
Bid/Ask
$84.30 / $84.70
Market Cap
$124.42 Bil
Volume/Avg
4.5 Mil / 5.4 Mil

Key Statistics

Price/Earnings (Normalized)
37.89
Price/Sales
8.21
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Core
Total Number of Employees
48,000
Website
https://www.bostonscientific.com

Competitors

Valuation

View More
Metric
BSX
JNJ
EW
Price/Earnings (Normalized)
 37.8915.3825.15
Price/Book Value
 6.105.425.28
Price/Sales
 8.214.586.87
Price/Cash Flow
 31.6917.3925.09
Price/Earnings
BSX
JNJ
EW

Financial Strength

Metric
BSX
JNJ
EW
Quick Ratio
 0.950.772.32
Current Ratio
 1.611.073.71
Interest Coverage
 8.6624.45—
Quick Ratio
BSX
JNJ
EW

Profitability

Metric
BSX
JNJ
EW
Return on Assets (Normalized)
 9.33%13.17%16.53%
Return on Equity (Normalized)
 17.03%32.42%22.97%
Return on Invested Capital (Normalized)
 11.85%20.93%19.92%
Return on Assets
BSX
JNJ
EW

Medical Devices Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
RhtdgwxlXwwrjm$197.7 Bil
 Stryker Corp
SYK
XgytcbknvXlyxr$135.3 Bil
 Medtronic PLC
MDT
QnyycxsqQklfsg$114.3 Bil
 Edwards Lifesciences Corp
EW
MzkylblfpQdsfg$39.2 Bil
 Koninklijke Philips NV ADR
PHG
YvcxXckg$30.6 Bil
 DexCom Inc
DXCM
WcwtqhbjtcXgckl$26.9 Bil
 Steris PLC
STE
CqqxdwskHbgqpp$23.1 Bil
 Zimmer Biomet Holdings Inc
ZBH
NhjfkwphywFmv$21.5 Bil
 Insulet Corp
PODD
WncftvvmtRcrpmb$16.3 Bil

Sponsor Center